TCM
PRTK

Touradji Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Touradji Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-833
Closed -$34K – 37
2013
Q4 		$34K Hold
833
– – 0.13% 64
2013
Q3 		$32K Buy
+833
New +$29.8K 0.1% 64

Other funds holding PRTK

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Touradji Capital Management's PRTK Position: Q1 2014 in Review

Touradji Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2014, closing a stake of 833 shares — an estimated $34K sold.

Touradji Capital Management first reported a position in PRTK in Q3 2013 and held it in 2 quarters. The position peaked at $34K in Q4 2013. 39 funds tracked by Wall St. Rank hold PRTK as of Q1 2014.

  • Touradji Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Touradji Capital Management sold 833 Paratek Pharmaceuticals, Inc. shares in Q1 2014, an estimated $34K.
  • Touradji Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2013 and held it in 2 quarters.
  • Touradji Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $34K in Q4 2013.
  • 39 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2014.

Based on Touradji Capital Management's 13F filing for Q1 2014, filed 5 May 2014.